2.A new drug BEOVU (brolucizumab) has been approved by the FDA for the treatment of wet macular degeneration. Wet age related macular degeneration is the main cause of blind registration in UK. BEOVU is manufactured by Novartis and is an anti-vascular endothelial growth factor, commonly known as an anti-VEGF. Anti-VEGF injections block the growth of new blood vessels. BEOVU is injected every month for three months and then every 8-12 weeks.
A new study shows that this drug may be more effective in treating leakage at the back of the eye due to wet age related macular degeneration as compared to drugs available previously and ma reduce the number of injections needed to control this blinding disease